SCHEMBL5458422

SCHEMBL5458422

NC(=O)c1c(NC(=O)C2CC2)sc2c(Cl)c(O)c(Cl)cc12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKA O14965 1/20 0.46
AURKB Q96GD4 1/20 0.46
FLT3 P36888 1/20 0.45
MAPK10 P53779 2/20 0.40
MAPK1 P28482 1/20 0.40
GFER P55789 1/20 0.40
KMT2A Q03164 7/20 0.39
MEN1 O00255 6/20 0.39
MAPT P10636 1/20 0.39
CASP3 P42574 1/20 0.37
SENP8 Q96LD8 1/20 0.37
SENP7 Q9BQF6 1/20 0.37
SENP6 Q9GZR1 1/20 0.37
TNIK Q9UKE5 1/20 0.36
HTT P42858 2/20 0.36
LMNA P02545 1/20 0.35
HPGD P15428 1/20 0.35
ALOX15 P16050 1/20 0.35
ALOX12 P18054 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5463015 0.84 AURKA (0.46) AURKAAURKBFLT3MAPK10MAPK1
SCHEMBL17625485 0.83 MEN1 (0.40) AURKAAURKBFLT3MAPK1KMT2A
SCHEMBL5456073 0.82 FLT3 (0.46) AURKAAURKBFLT3MAPK10MAPK1
SCHEMBL5449269 0.82 AURKA (0.48) AURKAAURKBFLT3MAPK10MAPK1
SCHEMBL5445044 0.82 AURKA (0.46) AURKAAURKBFLT3MAPK10MAPK1
SCHEMBL14361066 0.81 AURKA (0.41) AURKAAURKBFLT3MAPK10MAPK1
SCHEMBL5450635 0.81 AURKA (0.41) AURKAAURKBFLT3MAPK10MAPK1
SCHEMBL5454030 0.81 AURKA (0.48) AURKAAURKBFLT3MAPK10MAPK1
SCHEMBL17625483 0.81 AURKA (0.50) AURKAAURKB
Hydrochloric Acid SCHEMBL5460378 0.80 AURKA (0.41) AURKAAURKBFLT3MAPK10MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US claimed
EP-1670804-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC Biotech AG (DE) 2006-06-21 EP claimed
WO-2005023818-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC BIOTECH AG (DE) 2005-03-17 WO claimed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed
EP-1670804-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC Biotech AG (DE) 2006-06-21 EP disclosed
WO-2005023818-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC BIOTECH AG (DE) 2005-03-17 WO disclosed
WO-2005023818-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC BIOTECH AG (DE) 2005-03-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents TBCA, PARK7, NFATC1 AURKA 869/4885AURKB 585/4885FLT3 3509/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.